Related Experiment Video
Updated: Feb 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients
Grégoire Marret1, Ludovic Doucet1, Christophe Hennequin2
1Department of Cancer Medicine, Hôpital Saint Louis, Paris, France.
Background:
Abiraterone acetate (AA), an androgen biosynthesis inhibitor, is now a standard of care for men with metastatic, castration-sensitive and castration-resistant prostate cancer (mCRPC). Data exploring real-world toxicity and outcomes are scarce.
Methods:
Retrospective study on unselected patients with mCRPC on AA plus steroids.
Results:
93 patients were included in the study. Median duration of treatment by AA was 7.5 months (95% CI 5.7-12) among the 58 patients pretreated with chemotherapy, versus 12.7 months ( 95% CI 8.2-35.9) among the 33 chemo-naive patients. Median survivals would reach 13.4 months (95% CI 10.2-19.1) and 36.4 months (95% CI 24.7-41.5) respectively. Rates of hypokalemia, peripheral edema, hypertension, cardiac failure, and overall survival assessments in patients with and without prior chemotherapy were similar to that previously reported in phase 3 randomized trials. The median survival time without adverse event of special interest was 7.5 months for hypokalemia and hypertension, and 5.3 months for liver-function test abnormalities (it was not reached for cardiac disorders).
Conclusion:
Our findings provide further evidence for the survival benefits of AA with a low frequency of additional adverse events among unselected patients. In patients who have not developed hypokalemia or a transaminase increase within 7.5 and 5.3 months respectively, a lighter systematic monitoring may be considered.
Insights
Abiraterone acetate (AA) provides survival benefits for metastatic prostate cancer (mCRPC) patients. Real-world data show similar toxicity and outcomes to clinical trials, suggesting less intensive monitoring for some patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Abiraterone acetate (AA) is a standard treatment for metastatic prostate cancer (mPC).
- Real-world data on AA toxicity and outcomes in mPC are limited.
Purpose of the Study:
- To evaluate real-world toxicity and outcomes of abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Main Methods:
- Retrospective study of 93 unselected patients with mCRPC receiving AA plus steroids.
- Analysis of treatment duration, survival, and adverse events, comparing patients with and without prior chemotherapy.
Main Results:
- Median AA treatment duration was 7.5 months (pretreated) vs. 12.7 months (chemo-naive).
- Median survival was 13.4 months (pretreated) vs. 36.4 months (chemo-naive).
- Adverse event rates (hypokalemia, edema, hypertension, cardiac failure) were similar to Phase 3 trials.
Conclusions:
- AA demonstrates survival benefits with manageable toxicity in real-world mCRPC patients.
- Consider reduced monitoring for hypokalemia and liver function if stable for 7.5 and 5.3 months, respectively.
Related Concept Videos
Treatment Resistant Cancers
Survey Safety
Self-Efficacy
Household Wiring And Electrical Safety
Resistivity
Resistance

